Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

被引：0
|
作者：
Kuendgen, Andrea
Mueller-Thomas, Catharina
Urbaniak, Petra
Lauseker, Michael
Haferlach, Torsten
Alpermann, Tamara
Albuquerque, Andreia
Kohlmann, Alexander
Schnittger, Susanne
Hildebrandt, Barbara
Royer-Pokora, Brigitte
Gattermann, Norbert
Haas, Rainer
Germing, Ulrich
Goetze, Katharina
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2757.2757
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2757
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ANALYSIS OF POSSIBLE BIOMARKERS TO PREDICT RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Kuendgen, A.
    Mueller-Thomas, C.
    Lauseker, M.
    Urbaniak, P.
    Haferlach, T.
    Alpermann, T.
    Meggendorfer, M.
    Schnittger, S.
    Brings, C.
    Wulfert, M.
    Hildebrandt, B.
    Betz, B.
    Royer-Pokora, B.
    Haas, R.
    Gattermann, N.
    Germing, U.
    Goetze, K.
    LEUKEMIA RESEARCH, 2015, 39 : S82 - S82
  • [2] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
    Freyrie, A.
    Reda, G.
    Vincenti, D.
    Ferla, V.
    Orofino, N.
    Sciume, M.
    Guidotti, F.
    Cortelezzi, A.
    LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
  • [3] INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Ramos, S.
    Santos, M.
    Tenreiro, R.
    Pereira, M.
    Cortesao, E.
    Rito, L.
    Ribeiro, M. L.
    HAEMATOLOGICA, 2015, 100 : 474 - 475
  • [4] SINGLE INSTITUTION EXPERIENCE OF 5-AZACITIDINE THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Freyrie, A.
    Guidotti, F.
    Reda, G.
    Binda, F.
    Cortelezzi, A.
    HAEMATOLOGICA, 2012, 97 : 587 - 587
  • [5] Diagnostic of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Germing, Ulrich
    Haferlach, Torsten
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2015, 39 (05): : 291 - 299
  • [6] 5-Azacitidine Therapy in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia: a Single Institution Experience
    Freyrie, Alessandra
    Reda, Gianluigi
    Vincenti, Daniele
    Sciume, Mariarita
    Binda, Francesca
    Guidotti, Francesca
    Cortelezzi, Agostino
    BLOOD, 2012, 120 (21)
  • [7] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [8] Nature of Clinical Response and Depth of Molecular Response in Patients With TP53-Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated With Magrolimab With Azacitidine
    Johnson, Lisa
    Zhang, Yajia
    Li, Biao
    Aviles, Lisa
    Daver, Naval G.
    Vyas, Paresh
    Sallman, David A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S362 - S362
  • [9] Patterns of infection in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) receiving 5-azacitidine. Candidates for antifungal prophylaxis
    Falantes, J.
    Calderon, C.
    Marquez-Malaver, F. J.
    Aguilar, M.
    Martino, M. L.
    Gonzalez, J.
    Montero, M. I.
    Parody, R.
    Espigado, I.
    Perez-Simon, J. A.
    LEUKEMIA RESEARCH, 2013, 37 : S18 - S18
  • [10] Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine
    Johnson, Lisa
    Zhang, Yajia
    Li, Biao
    Aviles, Lisa
    Lal, Indu
    Ramsingh, Giri
    Daver, Naval
    Vyas, Paresh
    Sallman, David A.
    BLOOD, 2022, 140 : 6934 - 6935
12345